Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial
Authors' conclusion
Switching to a basal-bolus insulin regimen including biosimilar glargine resulted in marked improvements in HbA1c and diabetic ketoacidosis episodes. With relevant training, resources, and support, use of long-acting analogue insulin for treating T1D in Mali was feasible and acceptable to participants and healthcare professionals.
Study context
- Population
- Youth aged <25 years with T1D for ≥12 months, no prior analogue insulin, Mali
- Comparison
- Switch to long-acting biosimilar insulin glargine via reusable pens plus short-acting insulin via syringe vs continuing current human insulin via syringe
- Interventionn = 130
- Primary endpoint
- HbA1c, collected at baseline and 3-monthly
- Follow-up
- 12 months
Methodological detailstwo-group parallel design
- Two-group parallel design
Primary result
Mean HbA1c
Absolute difference
30 mmol/mol
95% CI −37 to −24
P < 0.001
By group
As reported in the abstract
Further findings
HbA1c ≥130 mmol/mol (≥14%) · baseline to 12 months
Baseline
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial. Diabet Med. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →